Background: A multicenter NCI-sponsored phase II study was conducted to analyze the safety and efficacy of the combination of ixabepilone with trastuzumab in patients with metastatic HER2-positive breast cancer.
introduction Trastuzumab, a humanized monoclonal antibody directed against the extracellular domain of HER2, is a critical component of treatment of HER2-positive breast cancer. Its use in combination with chemotherapy, particularly with taxanes, is well established and results in an improvement in progression-free survival (PFS) and overall survival [1, 2] . However, many patients have tumors that fail to respond to these agents, and nearly all patients with metastatic breast cancer will eventually progress [3] . Novel therapies for metastatic breast cancer are therefore needed.
The epothilones are a new class of antineoplastic agents that act by disrupting microtubule function [4, 5] . These agents bind to β-tubulin subunits and inhibit microtubule depolymerization, leading to mitotic arrest and apoptosis [6, 7] . Ixabepilone (BMS-247550, aza-epothilone B), a semi-synthetic analog of epothilone B, has demonstrated efficacy as monotherapy or in combination with capecitabine in anthracycline-and taxane-pretreated metastatic breast cancers and has recently been approved for use in refractory breast cancer [8] .
Several clinical trials have explored the efficacy of ixabepilone. Ixabepilone as a single agent was investigated in a phase II study in 126 patients with metastatic breast cancer resistant to an anthracycline, taxane, and capecitabine [9] . Patients received ixabepilone 40 mg/m 2 every 3 weeks and the objective response rate (ORR) was 11.5%, with an additional 50% of patients with stable disease. In a phase III study, 1221 women with anthracycline-pretreated or resistant and taxaneresistant locally advanced or metastatic breast cancer were randomized to ixabepilone (40 mg/m 2 every 3 weeks) in combination with capecitabine (2000 mg/m 2 daily for 2 weeks, followed by 1 week off ) or to capecitabine (2500 mg/m 2 given in the same schedule) alone [10] . In this study, ixabepilonecapecitabine was found to prolong PFS compared with capecitabine alone (5.8 versus 4.2 months, P = 0.003). These studies led to the FDA approval of ixabepilone, in combination with capecitabine, for the treatment of patients with metastatic or locally advanced breast cancer after failure of an anthracycline and a taxane and as monotherapy for the treatment of patients with metastatic or locally advanced breast cancer after failure of an anthracycline, taxane, and capecitabine.
Because trastuzumab has demonstrated synergistic activity in combination with several microtubule-stabilizing agents, we designed this trial to explore the safety and efficacy of ixabepilone in combination with trastuzumab. A preliminary analysis to identify tumor biomarkers that may predict sensitivity to trastuzumab was also performed.
patients and methods patients
Patients ≥18 years of age with measurable metastatic HER2-positive breast cancer were eligible. HER2 positivity was defined as 3+ positive for HER2 overexpression by immunohistochemistry (IHC) or amplified by fluorescence in situ hybridization (FISH) (FISH/CEP17 ≥2.0) by local review. Two cohorts of patients were eligible. Patients in cohort 1 could not have received prior chemotherapy or prior trastuzumab therapy for metastatic breast cancer, but may have received prior chemotherapy and/or trastuzumab therapy in the adjuvant setting, provided that trastuzumab therapy ended at least 12 months before study participation and chemotherapy ended 6 months before study participation. Patients in cohort 2 may have received up to two prior chemotherapy regimens for metastatic breast cancer. Patients in cohort 2 must have received one prior trastuzumab-containing regimen either in the metastatic setting or in the adjuvant setting. Patients with a history of brain metastases were eligible, provided that they had completed the treatment of their brain metastases at least 1 week before enrollment ECOG performance status of ≤2 and life expectancy of ≥6 months were required.
Key exclusion criteria included leptomeningeal carcinomatosis, prior epothilone therapy, motor or sensory neuropathy ≥grade 2 based on National Cancer Institute Common Terminology Criteria for Adverse Events version 3 (CTCAE), uncontrolled intercurrent illness, liver dysfunction [alanine transaminase >5× upper limit of normal (ULN) or total bilirubin >1.5× ULN), or cardiac dysfunction [left ventricular ejection fraction (LVEF) <50%]. The protocol was approved by the institutional review boards of participating institutions, and all patients provided written informed consent.
HERmark
® and p95 assays included grade 4 neutropenia lasting more than 7 days, febrile neutropenia, grade 4 thrombocytopenia or grade ≥3 thrombocytopenia with significant bleeding requiring transfusion, grade 3 diarrhea, and grade 2 neuropathy (motor or sensory) lasting ≥7 days or grade 3 neuropathy lasting ≥7 days.
In the event that a patient's ixabepilone was held, the patient received trastuzumab therapy at a dose of 2 mg/kg each week that ixabepilone was held. There were no dose or schedule adjustments for trastuzumab based on specific trastuzumab-related toxicity criteria, except cardiac toxicity. Patients underwent cardiac evaluation with an echocardiogram or multi gated acquisition scan at baseline, before study entry, and once again after six cycles (18 weeks) of treatment.
assessments evaluation of tumor response and toxicity assessment
Baseline tumor assessments were carried out within 2 weeks of the start of treatment by computed tomography or magnetic resonance imaging scans of the chest, abdomen, and pelvis. Patients were assessed for tumor response every 9 weeks for the first 27 weeks and then every 12 weeks thereafter. Radiologic assessments were evaluated by independent radiology review (IRR) using RECIST. The selection of target lesions by IRR and tumor assessments was done independently of investigator evaluations. The ORR was defined as the proportion of CR + PR among patients who started therapy, and the CBR was defined as the proportion of CR + PR + SD ≥ 24 weeks. TTP was measured from the time of study entry to time of tumor progression ( progressive disease), and TTF was measured from time of study entry to time of patient withdrawal from the study for either disease progression or removal for pre-determined toxicity criteria, whichever occurred first. Adverse events were evaluated at all visits. Toxic effects were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0.
statistical methods
There were separate statistical designs for each cohort using a one-stage design. The protocol called for enrolling a total of 60 patients (30 patients per cohort). For cohort 1, the regimen was considered worthy of further study if there were at least 13 confirmed responses out of 30 patients. The probability of declaring the regimen worthy of further study was 0.08 if the regimen had a response rate of 30% and was 0.91 if the regimen had a true original articles 1-23 cycles) . Toxicity was the most common reason for treatment discontinuation in cohort 1 (n = 8; 53%), whereas disease progression was the predominant reason for treatment discontinuation in cohort 2 (n = 12, 50%).
clinical activity
The overall response rate (CR or PR) was 44% in the intent-totreat population, and the response rate was numerically higher in cohort 1 (73%, 95% CI: 45%-92%) compared with cohort 2 (25%, 95% CI: 10%-47%; Table 2 ). Approximately half of all patients derived clinical benefit (56% with CR or PR or SD ≥24 weeks), with a CBR of 80% in cohort 1 and 42% in cohort 2. The median TTF was 6.6 months (95% CI: 4.2-11.0) for cohort 1 and 6.2 months (95% CI: 3.4-7.1) for cohort 2 ( Figure 1 ). The median TTP for cohort 1 was 11.0 months. There were insufficient data to determine the CI in cohort 1. The median TTP for cohort 2 was 6.7 months (95% CI: 4.3-12.3; Figure 2 ).
safety and tolerability
In this study, the most common adverse event of any grade was sensory neuropathy (82% of patients experienced grade ≥1 neuropathy). Neuropathy was mainly grade 1 or 2, with no grade 4 events recorded (Table 3 ). Other significant grade 2 or higher toxic effects included fatigue (38%), leukopenia (26%), joint pain (26%), neutropenia (21%), and myalgias (21%; Table 3 ). There were no reported events of the cardiac toxicity of any grade.
predictive biomarkers
In an effort to identify molecular biomarkers that were predictive of outcome in patients treated with ixabepilone and trastuzumab, we assessed H2D, H2T, and p95 protein levels using sensitive and quantitative proximity-based assays. Archival tumor tissue was available from 20 patients (7 from cohort 1 and 13 from cohort 2) and all 20 samples were evaluated with assays for H2T, H2D, and p95. H2T, H2D, and p95 data were obtained for all seven cases from cohort 1. Only six p95 cases from cohort 1 were used for correlation with outcomes, with one case excluded because of subthreshold total HER2 levels. Useful H2T and H2D data were obtained for Similar to what has been observed in previous studies of patients treated with trastuzumab-based regimens [13, 14] , higher levels of H2D were associated with best overall response, although this was of borderline significance (P = 0.061 using the Jonckheere-Terpstra test). Patients whose cancers had higher levels of H2D and H2T had longer TTP [hazard ratio (HR): 0.54 and 0.49, respectively] but this relationship was not statistically significant. The fact that these markers did not definitively separate responding patients from non-responders suggests the presence of other factors that influence sensitivity to ixabepilone and trastuzumab. One candidate is p95, a truncated form of HER2 that has constitutive catalytic activity and lacks the trastuzumabbinding domain [15] . Recent retrospective studies [12, 16] have suggested that elevated p95 levels predict poor outcome in patients with metastatic HER2 + breast cancer treated with trastuzumab containing regimens. In the current study, tumors with higher levels of p95 expression did have a numerically shorter median TTP, but this was not statistically significant (HR = 3.71, P = 0.39). However, we hypothesized that the relationship between p95 may be more apparent when controlling for the positive influence of H2T, as p95 is thought to negate the benefit gained by trastuzumab in HER2-positive breast cancer. Indeed, when using a bivariate continuous Cox analysis to independently assess the influences of p95 and H2T, p95 levels were associated with shorter TTP (HR = 3.6, P = 0.042).
discussion
This phase II study demonstrates the clinical activity of ixabepilone in combination with trastuzumab for metastatic HER2-positive breast cancer. The overall response rate was 44%, with a numerically higher response rate in cohort 1 compared with cohort 2 (73% versus 25%). The higher response rate observed in cohort 1 is likely a reflection of the fact that these patients had not received any prior chemotherapy or trastuzumab for metastatic breast cancer. Of patients in cohort 2, ∼40% had received one prior chemotherapy regimen in the metastatic setting, whereas ∼60% had received two prior regimens. In addition, all of these patients had received prior trastuzumab. Nonetheless, 25% of these pretreated patients experienced a PR to ixabepilone in combination with trastuzumab. Responses occurred rapidly, with most being reported by the first assessment at 9 weeks. Furthermore, the median TTF was 6.6 months for cohort 1 and 6.2 months for cohort 2.
The response rate of ixabepilone in combination with trastuzumab as first-line therapy for metastatic breast cancer (73%) is similar to response rates seen using trastuzumabtaxane combinations as first-line treatment. Studies have reported response rates of 50%-70% for trastuzumab in combination with docetaxel [17] [18] [19] and 62%-81% for trastuzumab in combination with paclitaxel [20] [21] [22] . Currently, the standard first-line therapy for metastatic HER2-positive breast cancer is a taxane in combination with trastuzumab and pertuzumab. Data suggest an 80.2% response rate for first line docetaxel-trastuzumab-pertuzumab, slightly better than that seen with ixabepilone and trastuzumab in this study [23] .
The clinical utility of any new therapy can be improved if there are biomarkers that can prospectively predict which patients are likely to respond and which are not allowing the therapy to be directed specifically to those patients with the greatest chance of deriving benefit. The need for such biomarkers is particularly acute in HER2 + breast cancer, where there are already a number of available targeted therapies and combinations from which to choose, with several additional agents likely to become available in the near future. Unfortunately, it has so far proven difficult to identify such markers. For trastuzumab, one potential marker of sensitivity is p95. Preclinical studies and retrospective clinical studies in patients with metastatic HER2 + disease suggest that those tumors with high levels of p95 are less likely to respond to trastuzumab-based therapy compared with those with minimal or no p95 expression [12, 16, 24] . However, this hypothesis has been called into question by recent data from three preoperative studies using very different IHC-based assays [25] [26] [27] . It is not known to what extent cross-reactivity with full-length HER2 in the p95 IHC assays contributed to this result.
In the current study, p95 levels by the VeraTag method were associated with shorter TTP (HR = 3.6, P = 0.042), but this relationship was only clearly observed when controlling for the effect of H2T levels. This analysis also utilized a novel highly sensitive and specific assay for p95 that is distinct from the assays used in the preoperative studies. It is unclear whether differences in the statistical approach, assay technology, and/or patient populations account for the conflicting results observed in the studies to date. Additional studies utilizing a uniform analysis technique are needed.
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Other notable toxic effects included leukopenia (21% grade ≥ 2) and neutropenia (21% grade ≥ 2); however, there were only two cases (5%) of febrile neutropenia. There were also a significant number of patients with grade 2 or higher myalgias (21%), which is similar to that reported in the phase II study of ixabepilone monotherapy [9] .
It has been demonstrated that cardiotoxicity is associated with trastuzumab therapy [28] . When trastuzumab is administered as monotherapy in the metastatic setting, the incidence of cardiac dysfunction has been calculated to be 7%, reaching 28% when administered in combination with an anthracycline and a cyclophosphamide [29] . In the current study, no symptomatic LVEF reductions were reported. This is the first study of ixabepilone in combination with trastuzumab and demonstrates that the combination is both safe and effective. Further studies are needed to explore response in taxane-resistant breast cancer and to compare efficacy to taxanes in combination with trastuzumab. 
